Skip to main content

Table 1 Pre- and post- treatment characteristics and pathologic outcomes of men undergoing radical prostatectomy at University of Pennsylvania, 1990–2012

From: The impact of body mass index on treatment outcomes for patients with low-intermediate risk prostate cancer

  Body mass index (kg/m2)   p-value
  <25 % 25–30 % >30 %  
iPSA (ng/ml)        0.95b
 median 5.1   5.4   5.2   
 mean 6.59   6.73   6.76   
 IQR 3.9–6.8   4.2–7.2   4.1–7.2   
Age (years)        0.37b
 median 60   60   59   
 mean 59.1   59.2   58.6   
 IQR 54–64   54–64   54–63   
Biopsy Gleason Score        0.46a
  ≤ 6 150 82 459 76 293 77  
 7 25 14 102 17 61 16  
 8 to 10 7 4 40 7 73 6  
Clinical T-stage        0.99a
 T1c 121 80 392 81 251 80  
 T2a 24 16 73 15 51 16  
 T2b 3 2 9 2 6 2  
 T2c 3 2 12 2 5 2  
Race        <0.001 a
 white 149 83 487 82 270 71  
 African-American/Black 31 17 106 18 112 29  
 other 4 2 9 2 2 0.5  
Pathologic Gleason Score        0.001 a
  ≤ 6 106 58 321 53 165 43  
 7 71 39 252 42 186 48  
 8 to 10 7 4 29 5 33 9  
Nodal Status        0.47a
 pN0 184 100 592 99 379 99  
 pN1 0 0 3 1 3 1  
Extraprostatic spread 39 21 130 22 117 30 0.004 a
Seminal Vesicle invasion 9 5 29 5 26 7 0.39a
Positive surgical margin 19 10 108 18 78 21 0.01 a
Additional Radiotherapy 1 0.6 11 2 8 2 0.39a
Hormonal Therapy 7 4 30 5 16 4 0.51a
No. of patients 184   602   384   
  1. NOTE. Boldfaced values represent statistically significant differences between groups
  2. Abbreviations: iPSA initial prostate-specific antigen, IQR interquartile range
  3. a P value derived from Person’s chi-square test
  4. b P value derived from analysis of variance model